Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.
Toon Van Gorp, MD, PhD
Advertisement
Toon Van Gorp, MD, PhD, a gynecologic oncologist at Universitair Ziekenhuis Leuven in Belgium.
Articles by Toon Van Gorp, MD, PhD
Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.
Advertisement
Latest Updated Articles
Dr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian CancerPublished: March 16th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5